We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.78%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.3B
AUM Growth
-$82M
Cap. Flow
-$615M
Cap. Flow %
-7.41%
Top 10 Hldgs %
34.19%
Holding
170
New
23
Increased
24
Reduced
50
Closed
20

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$104M
2
CI icon
Cigna
CI
+$77.7M
3
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$73.5M
4
MOH icon
Molina Healthcare
MOH
+$62.4M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$56.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$125M
2
BIIB icon
Biogen
BIIB
+$88.7M
3
SEM
Select Medical
SEM
+$77.6M
4
MRK icon
Merck
MRK
+$75.8M
5
FOLD
Amicus Therapeutics
FOLD
+$74.2M

Sector Composition

Rank Sector Weight
1 Healthcare 94.81%
2 Financials 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KIDS icon
151
OrthoPediatrics
KIDS
$510M
– –
-136,900
Closed -$3.65M
RARE icon
152
Ultragenyx Pharmaceutical
RARE
$2.56B
– –
-67,605
Closed -$5.2M
THC icon
153
Tenet Healthcare
THC
$22.6B
– –
-372,900
Closed -$12.5M
UHS icon
154
Universal Health Services
UHS
$10.1B
– –
-463,300
Closed -$51.6M
CLVS
155
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-100,000
Closed -$4.55M
GTS
156
DELISTED
Triple-S Management Corporation
GTS
– –
-305,662
Closed -$11.4M
MGLN
157
DELISTED
Magellan Health Services, Inc.
MGLN
– –
-251,383
Closed -$24.1M
ADMS
158
CALL
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-100,000
Closed -$2.58M
ALXN
159
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-70,000
Closed -$8.69M
AKRX
160
CALL
DELISTED
Akorn Inc
AKRX
– –
-200,000
Closed -$3.32M
KTWO
161
DELISTED
K2M Group Holdings, Inc
KTWO
– –
-843,205
Closed -$19M
STDY
162
DELISTED
SteadyMed Ltd
STDY
– –
-4,246,196
Closed -$19.1M
SHPG
163
DELISTED
Shire pic
SHPG
– –
-356,608
Closed -$60.2M
LPNT
164
DELISTED
LifePoint Health, Inc.
LPNT
– –
-513,200
Closed -$25M
3 4 5 6
7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2018 Portfolio in Review

As of Q3 2018, OrbiMed held 170 positions worth $8.3B, down 0.98% from $8.38B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed withdrew a net $615M in Q3 2018, closing 20 positions and reducing 50 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $125M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Principia Biopharma Inc. Common Stock worth $76.1M.

  • OrbiMed's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 2,605,713 shares worth $76.1M.
  • OrbiMed added most to Humana in Q3 2018, an estimated $104M increase.
  • OrbiMed's biggest Q3 2018 reduction was Biogen, cutting an estimated $88.7M.
  • OrbiMed fully exited Alnylam Pharmaceuticals in Q3 2018, selling an estimated $125M.
  • OrbiMed's ten largest holdings make up 34% of its $8.3B portfolio in Q3 2018.
  • OrbiMed opened 23 new positions and closed 20 in Q3 2018.
  • OrbiMed's portfolio value fell 0.98% quarter-over-quarter to $8.3B.

Based on OrbiMed's 13F filing for Q3 2018, filed 14 Nov 2018.